On    February 8 , the companies’ lobbying group   —    the Pharmaceutical    Care Management Association   —    released a video explaining why it    thinks certain kinds of pricing transparency is good , while other    types are bad .   " ’    The debate breaks down like this : PBMs negotiate rebates with the    different drugmakers .The terms of these    rebate contracts are variable and secret .